Zheng Xing Xing Ye Ri Bao·2026-01-14 08:58Market Overview - The biopharmaceutical sector experienced a decline of 0.9% on January 14, with Rongchang Biopharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aidi Pharmaceutical, closing at 19.83 with a rise of 16.72% and a trading volume of 242,400 shares, totaling 462 million yuan [1] - Wufan Biopharmaceutical, closing at 57.38 with an increase of 4.35% and a trading volume of 47,900 shares, totaling 272 million yuan [1] - Kangbuno, closing at 71.99 with a rise of 4.17% and a trading volume of 49,300 shares, totaling 355 million yuan [1] - Rongchang Biopharmaceutical saw a significant decline, closing at 103.34 with a drop of 9.72% and a trading volume of 196,700 shares, totaling 2.091 billion yuan [2] Capital Flow - The biopharmaceutical sector experienced a net outflow of 656 million yuan from institutional investors, while retail investors saw a net inflow of 407 million yuan [2] - Notable capital flows included: - Watson Biopharmaceuticals with a net inflow of 63.73 million yuan from institutional investors [3] - Kanghua Biopharmaceuticals with a net inflow of 18.92 million yuan from institutional investors [3] - Overall, retail investors contributed a net inflow of 4.07 billion yuan to the sector [2]